IllnessAutism, susceptibility
Summary
A curated panel containing >90 genes - incl. 7 guideline-curated genes - for the comprehensive analysis of the genetic susceptibility for autism spectrum diseases
174,6 kb (Extended panel: incl. additional genes)
- EDTA-anticoagulated blood (3-5 ml)
- array, 2. FRAX, 3. genes: MECP2, PTEN recommended by ACMG guidelines
NGS + [Sanger]
Gene panel
Selected genes
Name | Exon Length (bp) | OMIM-G | Referenz-Seq. | Heredity |
---|---|---|---|---|
DHCR7 | 1428 | NM_001360.3 | AR | |
FMR1 | 1899 | NM_002024.6 | XL | |
MECP2 | 1461 | NM_004992.4 | Sus | |
NF1 | 8457 | NM_001042492.3 | Sus | |
PTEN | 1212 | NM_000314.8 | Sus | |
SYNGAP1 | 4032 | NM_006772.3 | Sus | |
ADNP | 3309 | NM_015339.5 | AD | |
ANK2 | 11874 | NM_001148.6 | AD | |
ARID1B | 6750 | NM_001374820.1 | Sus | |
ASH1L | 8895 | NM_018489.3 | AD | |
ASXL3 | 6747 | NM_030632.3 | AD | |
CHD2 | 5487 | NM_001271.4 | Sus | |
CHD8 | 7746 | NM_001170629.2 | AD, Sus | |
CNTN4 | 3081 | NM_001206955.2 | Ass | |
CNTNAP2 | 3996 | NM_014141.6 | Sus | |
DDX3X | 1986 | NM_001193416.3 | Sus | |
DSCAM | 5985 | NM_001389.5 | n.k. | |
DYRK1A | 2292 | NM_001396.5 | AD | |
GRIN2B | 4455 | NM_000834.5 | AD | |
IRF2BPL | 2411 | NM_024496.4 | Sus | |
KATNAL2 | 1401 | NM_031303.3 | AD | |
KDM6A | 4206 | NM_021140.4 | XL | |
KMT2A | 11919 | NM_001197104.2 | Sus | |
KMT5B | 1182 | NM_017635.5 | AD | |
MYT1L | 3555 | NM_015025.4 | AD | |
NAA15 | 2601 | NM_057175.5 | AD | |
NLGN3 | 2487 | NM_018977.4 | XL | |
POGZ | 4233 | NM_015100.4 | AD | |
PTCHD1 | 2667 | NM_173495.3 | XLR | |
RELN | 10383 | NM_005045.4 | Sus | |
SCN2A | 6018 | NM_021007.3 | AD | |
SETD5 | 4329 | NM_001080517.3 | Sus | |
SHANK2 | 5404 | NM_012309.5 | AD | |
SHANK3 | 5386 | NM_001372044.2 | AD | |
SPAST | 1851 | NM_014946.4 | Sus | |
TBR1 | 2049 | NM_006593.4 | AD | |
TRIP12 | 5979 | NM_004238.3 | AD, Sus | |
TSC2 | 5424 | NM_000548.5 | Sus |
Informations about the disease
Autism spectrum disorders (ASD) are developmental disorders with particular social, communication and behavioural problems. Genetic alterations are risk factors for the development of ASD in addition to other mostly unknown causes. ASDs appear in early childhood, four times more frequently in boys than girls. Inheritance is generally multifactorial, i.e. several genes interact in a complex way with each other and with environmental influences. Inconspicuous genetic findings tend to be the rule.
Reference: https://www.awmf.org/leitlinien/detail/ll/028-018.html
- Alias: Autism susceptibility
- Allelic: Brugada syndrome 3 (CACNA1C)
- Allelic: Cardiac arrhythmia, ankyrin-B-related (ANK2)
- Allelic: Cowden syndrome 1 (PTEN)
- Allelic: Deafness, AR 97 (MET)
- Allelic: Epilepsy, familial temporal lobe, 7 (RELN)
- Allelic: Episodic ataxia, type 9 (SCN2A)
- Allelic: Fragile X tremor/ataxia syndrome(FMR1)
- Allelic: Glioma susceptibility 2 (PTEN)
- Allelic: Leukemia, juvenile myelomonocytic (NF1)
- Allelic: Lhermitte-Duclos syndrome (PTEN)
- Allelic: Long QT syndrome 4 (ANK2)
- Allelic: Long QT syndrome 8 (CACNA1C)
- Allelic: Meningioma (PTEN)
- Allelic: Neurofibromatosis, familial spinal (NF1)
- Allelic: Osteofibrous dysplasia, susceptibility to (MET)
- Allelic: Premature ovarian failure 1 (FMR1)
- Allelic: Renal cell carcinoma, papillary, 1, familial + somatic (MET)
- Allelic: Schizophrenia 15 (SHANK3)
- Allelic: Seizures, benign familial infantile, 3 (SCN2A)
- Allelic: Sinoatrial node dysfunction and deafness (CACNA1D)
- Allelic: VATER association, macrocephaly, ventriculomegaly (PTEN)
- Asperger syndrome susceptibility, XL (NLGN3)
- Asperger syndrome susceptibility, XL 2 (NLGN4)
- Autism susceptibility 15 (CNTNAP2)
- Autism susceptibility 16 (SLC9A9)
- Autism susceptibility 17 (SHANK2)
- Autism susceptibility [panelapp] (CACNA2D3)
- Autism susceptibility [panelapp] (DIP2C)
- Autism susceptibility [panelapp] (ERBIN)
- Autism susceptibility [panelapp] (ILF2)
- Autism susceptibility [panelapp] (INTS6)
- Autism susceptibility [panelapp] (KAT2B)
- Autism susceptibility [panelapp] (LEO1)
- Autism susceptibility [panelapp] (NCKAP1)
- Autism susceptibility [panelapp] (PHF3)
- Autism susceptibility [panelapp] (RANBP17)
- Autism susceptibility [panelapp] (SRSF11)
- Autism susceptibility [panelapp] (TAOK2)
- Autism susceptibility [panelapp] (UBN2)
- Autism susceptibility [panelapp] (USP15)
- Autism susceptibility to, 1 (EIF4E)
- Autism susceptibility to, 18 (CHD8)
- Autism susceptibility to, 20 (NLGN1)
- Autism susceptibility, XL 1 (NLGN3)
- Autism susceptibility, XL 2 (NLGN4)
- Autism susceptibility, XL 3 (MECP2)
- Autism susceptibility, XL 4 (PTCHD1)
- Autism susceptibility, XL 5 (RPL10)
- Autism susceptibility, XL 6 (TMLHE)
- Bainbridge-Ropers syndrome (ASXL3)
- Branched-chain keto acid dehydrogenase kinase deficiency (BCKDK)
- Coffin-Siris syndrome (ARID1B)
- Coffin-Siris syndrome 8 (SMARCC2)
- Combined immunodeficiencies with associated or syndromic features (KMT2A)
- Cone-rod dystrophy 7 (RIMS1)
- Cortical dysplasia-focal epilepsy syndrome (CNTNAP2)
- Desanto-Shinawi syndrome (WAC)
- Developmental + epileptic encephalopathy 11 (SCN2A)
- Developmental + epileptic encephalopathy 27 (GRIN2B)
- Developmental + epileptic encephalopathy 43 (GABRB3)
- Developmental + epileptic encephalopathy 94 (CHD2)
- Developmental delay with variable intellectual impairment + behavioral abnormalities (TCF20)
- Developmental delay, hypotonia, musculoskeletal defects, behavioral abnormalities (SRCAP)
- Dias-Logan syndrome (BCL11A)
- Down syndrome + congenital heart disease (DSCAM)
- Encephalopathy, neonatal severe (MECP2)
- Epilepsy, childhood absence, susceptibility to, 5C (GABRB3)
- Epilepsy, childhood absence, susceptibility to, 6 (CACNA1H)
- Epilepsy, idiopathic generalized, susceptibility to, 6 (CACNA1H)
- Erythermalgia, primary (SCN9A)
- Floating-Harbor syndrom (SRCAP)
- Fragile X syndrome (FMR1)
- Fraser syndrome 3 (GRIP1)
- Global developmental delay with speech + behavioral abnormalities (TNRC6B)
- Global developmental delay with/-out impaired intellectual development (CUX1)
- HP:0012759 0000717 0007018 0001250 0011471 (CMIP)
- Hao-Fountain syndrome (USP7)
- Helsmoortel-Van der Aa syndrome (ADNP)
- Hyperaldosteronism, familial, type IV (CACNA1H)
- Impaired intellectual development, distinctive facial features with/-out cardiac defects (MED13L)
- Insensitivity to pain, congenital (SCN9A)
- Intellectual developmental disorder with autism + speech delay (TBR1)
- Intellectual developmental disorder with language impairment with/-out autistic features (FOXP1)
- Intellectual developmental disorder with speech delay, autism, dysmorphic facies (CNOT3)
- Intellectual developmental disorder, AD 41 (TBL1XR1)
- Intellectual developmental disorder, AD 44, with microcephaly (TRIO)
- Intellectual developmental disorder, AD 45 (CIC)
- Intellectual developmental disorder, AD 50, with behavioral abnormalities (NAA15)
- Intellectual developmental disorder, AD 6, with/-out seizures (GRIN2B)
- Intellectual developmental disorder, AD 61 (MED13)
- Intellectual developmental disorder, AD 63, with macrocephaly (TRIO)
- Intellectual developmental disorder, AD 64 (RAB39B)
- Intellectual developmental disorder, AD 64 (ZNF292)
- Intellectual developmental disorder, AD 67 (GRIA1)
- Intellectual developmental disorder, AR 57 (MBOAT7)
- Intellectual developmental disorder, AR 65 (KDM5B)
- Intellectual developmental disorder, AR 76 (GRIA1)
- Intellectual developmental disorder, XL (NLGN4)
- Intellectual developmental disorder, XL syndromic 14 (UPF3B)
- Intellectual developmental disorder, XL, syndrome, Snijders Blok type (DDX3X)
- Intellectual developmental disorder, XL, syndromic LUBS type (MECP2)
- Intellectual developmental disorder, XL, syndromic, 13 (MECP2)
- Intellectual developmental disorder, XL, syndromic, 35 (RPL10)
- Intellectual disability, autism (BAZ2B)
- KBG syndrome (ANKRD11)
- Kabuki syndrome 2 (KDM6A)
- Kleefstra syndrome 2 (KMT2C)
- Lissencephaly 2 [Norman-Roberts type] (RELN)
- Lymphangioleiomyomatosis (TSC1)
- Macrocephaly/autism syndrome (PTEN)
- Mental retardation, AD 23 (SETD5)
- Mental retardation, AD 28 (ADNP)
- Mental retardation, AD 39 (MYT1L)
- Mental retardation, AD 49 (TRIP12)
- Mental retardation, AD 5 (SYNGAP)
- Mental retardation, AD 51 (KMT5B)
- Mental retardation, AD 52 (ASH1L)
- Mental retardation, AD 7 (DYRK1A)
- Mental retardation, AR 27 (LINS1)
- Microcephaly 18, primary, AD (WDFY3)
- Myoclonic-atonic epilepsy (SLC6A1)
- Neurodevelopmental disorder with hypotonia, impaired expressive language +/- seizures (DEAF1)
- Neurodevelopmental disorder with regression, abn. movements, speech loss, seizures (IRF2BPL)
- Neurodevelopmental disorder with/-out autism/seizures (CUL3)
- Neurofibromatosis, type 1 (NF1)
- Neurofibromatosis-Noonan syndrome (NF1)
- Neuropathy, hereditary sensory + autonomic, type IID (SCN9A)
- Parkinson disease 11 (GIGYF2)
- Paroxysmal extreme pain disorder (SCN9A)
- Phelan-McDermid syndrome [Rett syndrome-like phenotype] (SHANK3)
- Pierpont syndrome (TBL1XR1)
- Pitt-Hopkins like syndrome 1 (CNTNAP2)
- Pitt-Hopkins-like syndrome 2 (NRXN1)
- Primary aldosteronism, seizures + neurologic abnormalities (CACNA1D)
- Pseudohypoaldosteronism, type IIE (CUL3)
- Respiratory infections, short stature, hypertelorism, hairy elbows, dev. delay, ID (KMT2A)
- Rett syndrome (MECP2)
- Rett syndrome, atypical (MECP2)
- Rett syndrome, preserved speech variant (MECP2)
- Schaaf-Yang syndrome (MAGEL2)
- Schizophrenia, susceptibility to, 17 (NRXN1)
- Small fiber neuropathy (SCN9A)
- Smith-Lemli-Opitz syndrome (DHCR7)
- Spastic paraplegia 4, AD (SPAST)
- TRIP12-related intellectual disability with/-out ASD (TRIP12)
- Timothy syndrome (CACNA1C)
- Tuberous sclerosis-1 (TSC1)
- Tuberous sclerosis-2 (TSC2)
- Vulto-van Silfout-de Vries syndrome (DEAF1)
- Watson syndrome (NF1)
- White-Sutton syndrome [mental retardation, AD 37] (POGZ)
- Wiedemann-Steiner syndrome (KMT2A)
- AD
- AR
- Ass
- Sus
- XL
- XLR
- n.k.
- Multiple OMIM-Ps
Bioinformatics and clinical interpretation
Test-Stärken
- DAkkS-akkreditiertes Labor
- EU-Richtlinie für IVD in Umsetzung
- Qualitäts-kontrolliert arbeitendes Personal
- Leistungsstarke Sequenzierungstechnologien, fortschrittliche Target-Anreicherungsmethoden und Präzisions-Bioinformatik-Pipelines sorgen für überragende analytische Leistung
- Sorgfältige Kuratierung klinisch relevanter und wissenschaftlich begründeter Gen-Panels
- eine Vielzahl nicht Protein-kodierender Varianten, die in unseren klinischen NGS-Tests mit erfasst werden
- unser strenges Variantenklassifizierungsschema nach ACMG-Kriterien
- unser systematischer klinischer Interpretations-Workflow mit proprietärer Software ermöglicht die genaue und nachvollziehbare Verarbeitung von NGS-Daten
- unsere umfassenden klinischen Aussagen
Testeinschränkungen
- Gene mit eingeschränkter Abdeckung werden gekennzeichnet
- Gene mit kompletten oder partiellen Duplikationen werden gekennzeichnet
- es wird angenommen, dass ein Gen suboptimal abgedeckt ist, wenn >90% der Nukleotide des Gens bei einem Mapping-Qualitätsfaktor von >20 (MQ>20) nicht abgedeckt sind
- die Sensitivität der Diagnostik zur Erkennung von Varianten mit genannten Testeinschränkungen ist möglicherweise begrenzt bei:
- Gen-Konversionen
- komplexe Inversionen
- Balancierte Translokationen
- Mitochondriale Varianten
- Repeat-Expansionen, sofern nicht anders dokumentiert
- nicht kodierende Varianten, die Krankheiten verursachen, die von diesem Panel nicht mit abgedeckt werden
- niedriger Mosaik-Status
- Repeat-Blöcke von Mononukleotiden
- Indels >50bp (Insertionen-Deletionen)
- Deletionen oder Duplikationen einzelner Exons
- Varianten innerhalb von Pseudogenen
- die analytische Sensitivität kann geringer ausfallen werden, wenn die DNA nicht von amedes genetics extrahiert wurde
Laboratory requirement
Die in grün gezeigten Gene sind kuratiert und werden als Gen-Panel untersucht. Eine Erweiterung des Panels (blau gezeigte Gene, jeweils ebenfalls kuratiert) kann auf Anfrage erfolgen. Sofern unter "Erweitertes Panel" ein Minuszeichen angezeigt wird, sind nur Core-/Basis-Gene verfügbar.
Für die Anforderung einer genetischen Untersuchung senden Sie uns bitte die Krankheits-ID auf einem Überweisungsschein. Bitte die Material-Angabe beachten.
Für privat versicherte Patienten empfehlen wir einen Antrag auf Kostenübernahme bei der Krankenversicherung.
Die Untersuchung wird auch für Selbstzahler angeboten.